Drug Duo Represents 'Potential Paradigm Shift' for Rare Eye Cancer

Darovasertib plus Xalkori is showing promise for the treatment of patients with metastatic uveal melanoma, according to results from an ongoing study.

Related Keywords

Darrin Beaupre ,Meredith Mckean ,Drug Administration ,Sarah Cannon Research Institute ,Collateral Damage From Uveal Melanoma ,Rare Cancer ,Uveal Melanoma ,Rare Cancers ,